lacutamab (IPH4102) / Innate 
Welcome,         Profile    Billing    Logout  
 3 Diseases   3 Trials   3 Trials   127 News 


12»
  • ||||||||||  lacutamab (IPH4102) / Innate
    Lacutamab in patients with relapsed and refractory S (Hall A - Posters and Exhibits; Poster Bd #: 169) -  Apr 23, 2025 - Abstract #ASCO2025ASCO_931;    
    P2
    The long term follow-up data from TELLOMAK study in a R/R SS population previously treated with 2 or more prior systemic therapies including mogamulizumab, confirm that lacutamab shows promising clinical activity with ORR 42.9% (95% CI 31.4-55.1) and median duration of response of 25.6 months (11.0, NE) and an overall favourable safety profile. These data support the further development of lacutamab in an effort to bring improved treatments to patients with SS.
  • ||||||||||  Poteligeo (mogamulizumab-kpkc) / Kyowa Kirin, Adcetris (brentuximab vedotin) / Takeda, Pfizer, lacutamab (IPH4102) / Innate
    Journal:  Therapeutic advances for Cutaneous T Cell Lymphoma. (Pubmed Central) -  Mar 25, 2025   
    Lacutamab has recently completed an international trial, both in SS and MF...Kinase inhibitors and Chimeric Antigen Receptor (CAR)-T Therapy are promising new treatments. Finally, recent studies have demonstrated that allogeneic hematopoietic stem-cell transplantation can increase survival and quality of life in patients with advanced CTCL.
  • ||||||||||  lacutamab (IPH4102) / Innate
    Trial completion date, Trial primary completion date:  KILT: Study of Lacutamab in Peripheral T-cell Lymphoma (clinicaltrials.gov) -  Mar 5, 2025   
    P2,  N=56, Recruiting, 
    Finally, recent studies have demonstrated that allogeneic hematopoietic stem-cell transplantation can increase survival and quality of life in patients with advanced CTCL. Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2025 --> Jan 2026
  • ||||||||||  lacutamab (IPH4102) / Innate
    Lacutamab in Patients with Relapsed and/or Refractory S (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_4954;    
    P2
    In skin, while no association was observed between response to lacutamab and KIR3DL2-expression in biopsies or KIR3DL2+ cell density at baseline, higher baseline infiltration by CD16-expressing cells, in particular CD16-expressing CD68+ macrophages was associated with better response in this compartment, consistent with lacutamab mechanism of action. These data confirm at a translational level the activity of lacutamab in the clinical trial setting, and its potential as a compelling future treatment option for CTCL patients with unmet need.
  • ||||||||||  Poteligeo (mogamulizumab-kpkc) / Kyowa Kirin, Adcetris (brentuximab vedotin) / Takeda, Pfizer, lacutamab (IPH4102) / Innate
    Review, Journal:  Advances in the pharmacological management of cutaneous T-cell lymphoma. (Pubmed Central) -  Jun 18, 2024   
    Secondly, a more profound comprehension of the tumor microenvironment is imperative to optimize the landscape of targetable molecules. Lastly, the undertaking of studies on combination regimens should be encouraged as it enhances therapy efficacies by synergistically combining agents with diverse modes of action.
  • ||||||||||  lacutamab (IPH4102) / Innate
    Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Results from the TELLOMAK phase 2 trial. (Hall A; Poster Bd #: 65) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_2417;    
    P2
    The data from the heavily pre-treated MF population enrolled to the TELLOMAK study confirms promising clinical activity of lacutamab regardless of KIR3DL2 expression, with a favorable safety and tolerability profile. These data support the further development of lacutamab in an effort to bring improved treatments to patients with CTCL.
  • ||||||||||  Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas. (Pubmed Central) -  Nov 28, 2023   
    The expression of these epitopes on neoplastic cells in skin biopsies or blood samples plays a central role in the management of PCTCL patients. This narrative review aims to provide readers with an update on the latest advances in the newest therapeutic options for PCTCLs.
  • ||||||||||  lacutamab (IPH4102) / Innate
    Lacutamab in Patients with Relapsed and Refractory S (Grand Hyatt - Grand Hall B) -  Nov 3, 2023 - Abstract #ASH2023ASH_1203;    
    P2
    Conclusion In this SS cohort from the TELLOMAK study, our data confirm that lacutamab monotherapy shows promising clinical activity in a R/R population previously treated with 2 or more prior systemic therapies including mogamulizumab, and an overall favourable safety profile. Continued evaluation of this new targeted treatment option for patients with SS is warranted.
  • ||||||||||  lacutamab (IPH4102) / Innate
    KIR3DL2 also represents a novel therapeutic target in non-cutaneous aggressive systemic peripheral T-cell lymphomas () -  Jul 24, 2023 - Abstract #EORTCCLTF2023EORTC_CLTF_127;    
    Objectives: Our ojectives were to (1) investigate KIR3DL2 expression in a large cohort of PTCL patients, (2) assess the anti-tumor activity of lacutamab on cell lines and primary PTCL cells, (3) study the DNA-methylation status of the KIR3DL2 gene promoter, and (4) assess whether hypomethylating agents or chemotherapy (gemcitabine and oxaliplatin) can increase lacutamab efficacy through the modulation of KIR3DL2 expression...CpG island methylation was decreased by 5-azacitidine in cell lines, resulting in increased KIR3DL2 levels... This study supports lacutamab as a therapeutic option in KIR3DL2+ PTCLs and provides a rationale for combining lacutamab with conventional chemotherapy.
  • ||||||||||  lacutamab (IPH4102) / Innate
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  TELLOMAK: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (clinicaltrials.gov) -  Jul 14, 2023   
    P2,  N=170, Active, not recruiting, 
    The future adoption of the revised guidelines is welcomed by the CTCL community. Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Oct 2024 | Trial primary completion date: Mar 2023 --> Oct 2023
  • ||||||||||  lacutamab (IPH4102) / Innate
    Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_2486;    
    P2
    To date vorinostat, is the only drug that has been approved by the FDA for the treatment of pts with CTCL with cutaneous manifestations who have received 2 prior systemic therapies...Cohort 1, for which preliminary data is reported here, is designed to evaluate safety and efficacy of single agent lacutamab in pts with relapsed/refractory SS after at least 2 prior systemic therapies including mogamulizumab...Conclusion In this highly refractory SS cohort from the TELLOMAK study, our preliminary data demonstrate that lacutamab shows clinical activity and favourable safety profile. Continued evaluation of this new targeted treatment option for patients with SS is warranted.
  • ||||||||||  lacutamab (IPH4102) / Innate
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  TELLOMAK: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (clinicaltrials.gov) -  Jun 22, 2022   
    P2,  N=166, Recruiting, 
    The trial is currently enrolling in 11 medical centers in the US and South Korea. Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2022 --> Mar 2023
  • ||||||||||  Poteligeo (mogamulizumab) / Kyowa Kirin, Adcetris (brentuximab vedotin) / Seagen, Takeda, lacutamab (IPH4102) / Innate
    Journal:  New biotherapies for the treatment of cutaneous T-cell lymphomas. (Pubmed Central) -  Jun 19, 2022   
    Finally, immune checkpoint inhibitors have shown clinical benefit in open-label phase 2 studies in cutaneous T-cell lymphomas. This review focuses on the new biotherapies currently used in cutaneous T-cell lymphomas.
  • ||||||||||  lacutamab (IPH4102) / Innate
    Enrollment open:  KILT: Study of Lacutamab in Peripheral T-cell Lymphoma (clinicaltrials.gov) -  Dec 6, 2021   
    P2,  N=56, Recruiting, 
    This review focuses on the new biotherapies currently used in cutaneous T-cell lymphomas. Not yet recruiting --> Recruiting
  • ||||||||||  lacutamab (IPH4102) / Innate
    Trial completion, Trial completion date, Trial primary completion date:  Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) (clinicaltrials.gov) -  Jan 20, 2021   
    P1,  N=44, Completed, 
    Updated results on all stage 1 pts from cohort 2 and 3 will be presented. Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2020 | Trial primary completion date: Dec 2019 --> Apr 2020
  • ||||||||||  IPH-4102 / Innate
    Journal:  A KIR3DL2 Antibody Is Safe and Active in Cutaneous T-cell Lymphoma. (Pubmed Central) -  Jul 10, 2019   
    A multi-cohort, phase 2 trial (TELLOMAK) is underway to confirm the activity in patients with Sézary syndrome and explore the role of IPH4102 in other subtypes of T-cell lymphomas that express KIR3DL2. KIR3DL2 antibody IPH4102 exhibits a favorable safety profile and preliminary evidence of efficacy.
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Review, Journal:  Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome. (Pubmed Central) -  Jun 22, 2019   
    Novel agents in advanced development include the monoclonal antibody IPH4102,duvelisib,and the new modified formulation of denileukin diftitox. The choice of agents for patients is typically a balance of patient factors (age, co-morbidities, geographic location), relative efficacy and toxicity.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Afinitor (everolimus) / Novartis
    Review, Journal:  Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome. (Pubmed Central) -  Jun 14, 2019   
    This review provides a discussion of the recent and future promising therapeutic approaches in the management of advanced MF/SS. These include mogamulizumab, brentuximab vedotin, alemtuzumab, immune checkpoint inhibitors, IPH4102 (anti-KIR3DL2 antibody), histone deacetylase inhibitors (vorinostat, romidepsin, panobinostat, belinostat, and resminostat), pralatrexate, forodesine, denileukin diftitox, duvelisib, lenalidomide, and everolimus.
  • ||||||||||  lacutamab (IPH4102) / Innate
    Enrollment open, Combination therapy, Metastases:  TELLOMAK: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (clinicaltrials.gov) -  May 22, 2019   
    P2,  N=250, Recruiting, 
    These include mogamulizumab, brentuximab vedotin, alemtuzumab, immune checkpoint inhibitors, IPH4102 (anti-KIR3DL2 antibody), histone deacetylase inhibitors (vorinostat, romidepsin, panobinostat, belinostat, and resminostat), pralatrexate, forodesine, denileukin diftitox, duvelisib, lenalidomide, and everolimus. Not yet recruiting --> Recruiting